Skip to content
Evigrade
CriticalProkinetic, 5-HT4 serotonin receptor agonist (withdrawn EU/US)×Atypical antipsychotic – indole derivative

Updated · Methodology

Mechanism

Ziprasidone itself causes mild to moderate, dose-dependent QT prolongation (ziprasidone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The Spanish ziprasidone SmPC names cisapride among QT-prolonging drugs. It warns that no studies have been done with such drugs and that an additive effect on QT cannot be excluded (ziprasidone SmPC, AEMPS). In controlled trials in adults, ziprasidone at the highest recommended dose of 160 mg a day increased the corrected QT interval (QTc) by about 10 ms more than placebo (ziprasidone label, US Food and Drug Administration, FDA). The documents give no data on whether ziprasidone changes cisapride levels. According to the Spanish SmPC, ziprasidone is unlikely to change the metabolism of drugs handled by CYP2D6 and CYP3A4 to a clinically relevant degree (ziprasidone SmPC, AEMPS).

Symptoms

QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG). A ventricular arrhythmia causes sudden strong palpitations, dizziness or fainting and can lead to cardiac arrest. Palpitations, vertigo, fainting or seizures during ziprasidone treatment may signal a malignant arrhythmia (ziprasidone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Post-marketing reports describe infrequent cases of torsade de pointes in people taking ziprasidone who had several confounding risk factors (ziprasidone SmPC, AEMPS). Low blood potassium and magnesium increase the risk of malignant arrhythmias (ziprasidone SmPC, AEMPS).

Management

The combination is contraindicated. The Spanish ziprasidone summaries of product characteristics (SmPCs), for both the originator and the generic, contraindicate ziprasidone with QT-prolonging drugs and name cisapride among them (ziprasidone SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). The US ziprasidone label also contraindicates QT-prolonging drugs, but cisapride is not on its list (ziprasidone label, US Food and Drug Administration, FDA). Cisapride is not in the Spanish medicines register CIMA, so the ziprasidone documents set the level of risk. If a person takes cisapride obtained in another country, do not prescribe ziprasidone with it (ziprasidone SmPC, AEMPS). No document states how long to wait after stopping ziprasidone before starting cisapride. The mean terminal half-life of oral ziprasidone is 6.6 hours (ziprasidone SmPC, AEMPS). Ziprasidone is contraindicated in known QT prolongation, congenital long QT syndrome, recent acute myocardial infarction and uncompensated heart failure. Correct low potassium and magnesium before starting treatment (ziprasidone SmPC, AEMPS). In stable heart disease, consider an electrocardiogram (ECG) before starting. If the corrected QT interval (QTc) exceeds 500 ms, the SmPC recommends stopping treatment (ziprasidone SmPC, AEMPS).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Cisapride

Other interactions with Ziprasidone